40 results on '"Graham, Barney S."'
Search Results
2. Antigen spacing on protein nanoparticles influences antibody responses to vaccination.
- Author
-
Ellis, Daniel, Dosey, Annie, Boyoglu-Barnum, Seyhan, Park, Young-Jun, Gillespie, Rebecca, Syeda, Hubza, Hutchinson, Geoffrey B., Tsybovsky, Yaroslav, Murphy, Michael, Pettie, Deleah, Matheson, Nick, Chan, Sidney, Ueda, George, Fallas, Jorge A., Carter, Lauren, Graham, Barney S., Veesler, David, Kanekiyo, Masaru, and King, Neil P.
- Abstract
Immunogen design approaches aim to control the specificity and quality of antibody responses elicited by next-generation vaccines. Here, we use computational protein design to generate a nanoparticle vaccine platform based on the receptor-binding domain (RBD) of influenza hemagglutinin (HA) that enables precise control of antigen conformation and spacing. HA RBDs are presented as either monomers or native-like closed trimers that are connected to the underlying nanoparticle by a rigid linker that is modularly extended to precisely control antigen spacing. Nanoparticle immunogens with decreased spacing between trimeric RBDs elicit antibodies with improved hemagglutination inhibition and neutralization potency as well as binding breadth across diverse H1 HAs. Our "trihead" nanoparticle immunogen platform provides insights into anti-HA immunity, establishes antigen spacing as an important parameter in structure-based vaccine design, and embodies several design features that could be used in next-generation vaccines against influenza and other viruses. [Display omitted] • Computational design of a closed trimeric HA RBD ("trihead") antigen platform • Design of a rigid, extendable linker enables precise variation of antigen spacing • Decreased antigen spacing of triheads elicits responses with increased breadth and potency • Changes to antigen spacing alter epitope specificities of vaccine-elicited antibodies Ellis et al. used computational protein design to create a series of trimeric hemagglutinin-head-based nanoparticles with differing extension domains to vary antigen spacing. They found that decreased antigen spacing leads to a more potent and broad immune response as well as changes in epitope specificity. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Immunological goals for respiratory syncytial virus vaccine development.
- Author
-
Graham, Barney S
- Subjects
- *
VIRAL vaccines , *RESPIRATORY syncytial virus , *HUMORAL immunity , *VIRAL tropism , *IMMUNE response - Abstract
• Immunological goals for vaccination depend on whether it is for primary induction or boosting of pre-existing immunity. • Boosting neutralizing activity is the major goal for maternal and elderly populations. • High potency neutralizing activity is primarily directed to the RSV F glycoprotein and is conformation-dependent. • For antigen-naïve infants, avoidance of immunopathology is as important as induction of protective immunity. • New technologies have informed precision vaccine design and yielded new interventions to reduce the burden of RSV disease. Defining the immunological goals for respiratory syncytial virus (RSV) vaccination requires understanding of RSV biology and tropism, mechanisms of cell-to-cell spread and immunity, epidemiology, and transmission dynamics. The immunological goals for a particular vaccine would be product-specific based on antigen selection, delivery approach, and target population. There are many ways to achieve immunity against RSV infection involving innate and adaptive responses, humoral, and cellular effector mechanisms, and mucosal and systemic responses. Both protective and pathological immune response patterns have been demonstrated in animal models and humans. In this short commentary, the entire information matrix that may inform the design of particular vaccine candidates cannot be fully reviewed, but the rationale behind the major vaccine approaches in key target populations will be discussed. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
4. Extrapulmonary thoracic disease caused by Blastomyces dermatitidis
- Author
-
Neuzil, Kathleen M., Mitchell, Holly C., Loyd, James E., Lagerstrom, Carl F., Hammon, Jr., John W., and Graham, Barney S.
- Subjects
Blastomycosis -- Case studies ,Health ,Case studies - Abstract
A case of blastomycosis is reported involving the mediastinum and compromising the plexus brachialis. The pathology, pathophysiology, and treatment of this patient and of a previously reported patient are discussed [...]
- Published
- 1994
5. Vaccine development for respiratory syncytial virus.
- Author
-
Graham, Barney S
- Abstract
Respiratory syncytial virus (RSV) is an important and ubiquitous respiratory pathogen for which no vaccine is available notwithstanding more than 50 years of effort. It causes the most severe disease at the extremes of age and in settings of immunodeficiency. Although RSV is susceptible to neutralizing antibody, it has evolved multiple mechanisms of immune evasion allowing it to repeatedly infect people despite relatively little genetic diversity. Recent breakthroughs in determining the structure and antigenic content of the fusion (F) glycoprotein in its metastable untriggered prefusion form (pre-F) and the stable rearranged postfusion form (post-F) have yielded vaccine strategies that can induce potent neutralizing antibody responses and effectively boost pre-existing neutralizing activity. In parallel, novel live-attenuated and chimeric virus vaccine candidates and other novel approaches to deliver vaccine antigens have been developed. These events and activities have aroused optimism and a robust pipeline of potential vaccine products that promise to provide a means to reduce the public health burden of RSV infection. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
6. Challenges and opportunities in RSV vaccine development: Meeting report from FDA/NIH workshop.
- Author
-
Roberts, Jeffrey N., Graham, Barney S., Karron, Ruth A., Munoz, Flor M., Falsey, Ann R., Anderson, Larry J., Marshall, V., Kim, Sonnie, and Beeler, Judy A.
- Subjects
- *
DRUG development , *PEDIATRIC respiratory diseases , *IMMUNOCOMPROMISED patients - Abstract
Respiratory syncytial virus (RSV) is the most common cause of serious acute lower respiratory illness in infants and young children and a significant cause of disease burden in the elderly and immunocompromised. There are no licensed RSV vaccines to address this significant public health need. While advances in vaccine technologies have led to a recent resurgence in RSV vaccine development, the immune correlates of protection against RSV and the immunology of vaccine-associated enhanced respiratory disease (ERD) remain poorly understood. FDA’s Center for Biologics Evaluation and Research (CBER) and NIH’s National Institute of Allergy and Infectious Diseases (NIAID) organized and co-sponsored an RSV Vaccines Workshop in Bethesda, Maryland on June 1 and 2, 2015. The goal of the conference was to convene scientists, regulators, and industry stakeholders to discuss approaches to RSV vaccine development within the context of three target populations - infants and children, pregnant women, and individuals >60 years of age. The agenda included topics related to RSV vaccine development in general, as well as considerations specific to each target population, such as clinical and serological endpoints. The meeting focused on vaccine development for high income countries (HIC), because issues relevant to vaccine development for low and middle income countries (LMIC) have been discussed in other forums. This manuscript summarizes the discussion of clinical, scientific, and regulatory perspectives, research gaps, and lessons learned. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
7. Broadly Neutralizing Activity of Zika Virus-Immune Sera Identifies a Single Viral Serotype.
- Author
-
Dowd, Kimberly A., DeMaso, Christina R., Pelc, Rebecca S., Speer, Scott D., Smith, Alexander R.Y., Goo, Leslie, Platt, Derek J., Mascola, John R., Graham, Barney S., Mulligan, Mark J., Diamond, Michael S., Ledgerwood, Julie E., and Pierson, Theodore C.
- Abstract
Summary Recent epidemics of Zika virus (ZIKV) have been associated with congenital malformation during pregnancy and Guillain-Barré syndrome. There are two ZIKV lineages (African and Asian) that share >95% amino acid identity. Little is known regarding the ability of neutralizing antibodies elicited against one lineage to protect against the other. We investigated the breadth of the neutralizing antibody response following ZIKV infection by measuring the sensitivity of six ZIKV strains to neutralization by ZIKV-confirmed convalescent human serum or plasma samples. Contemporary Asian and early African ZIKV strains were similarly sensitive to neutralization regardless of the cellular source of virus. Furthermore, mouse immune serum generated after infection with African or Asian ZIKV strains was capable of neutralizing homologous and heterologous ZIKV strains equivalently. Because our study only defines a single ZIKV serotype, vaccine candidates eliciting robust neutralizing antibody responses should inhibit infection of both ZIKV lineages, including strains circulating in the Americas. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
8. Vaccines against respiratory syncytial virus: The time has finally come.
- Author
-
Graham, Barney S.
- Subjects
- *
RESPIRATORY syncytial virus infection vaccines , *PUBLIC health , *INFANT diseases , *NEWBORN infants , *ANTIGENS - Abstract
Respiratory syncytial virus causes a significant public health burden, particularly in very young infants and the frail elderly. The legacy of enhanced RSV disease (ERD) from a whole formalin-inactivated RSV vaccine, and the complex biology of the virus and the neonate have delayed the development of effective vaccines. However, new insights into factors associated with ERD and breakthroughs in understanding the antigenic structure of the fusion (F) glycoprotein have increased optimism that vaccine development is possible. This has led to investment of time and resources by industry, regulatory authorities, governments, and nonprofit organizations to develop the infrastructure needed to make the advanced clinical development of RSV vaccine candidates a reality. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
9. Determinants of early life immune responses to RSV infection.
- Author
-
Ruckwardt, Tracy J, Morabito, Kaitlyn M, and Graham, Barney S
- Abstract
Respiratory syncytial virus causes significant morbidity and mortality in both developed and developing countries, and a vaccine that adequately protects from severe disease remains an important unmet need. RSV disease has an inordinate impact on the very young, and the physical and immunological immaturity of early life complicates vaccine design. Defining and targeting the functional capacities of early life immune responses and controlling responses during primary antigen exposure with selected vaccine delivery approaches will be important for protecting infants by active immunization. Alternatively, vaccination of older children and pregnant mothers may ameliorate disease burden indirectly until infants reach about six months of age, when they can generate more effective anti-RSV immune responses. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
10. Novel antigens for RSV vaccines.
- Author
-
Graham, Barney S, Modjarrad, Kayvon, and McLellan, Jason S
- Subjects
- *
ANTIGEN analysis , *RESPIRATORY syncytial virus infection vaccines , *INFANT diseases , *ETIOLOGY of diseases , *DRUG development - Abstract
Respiratory syncytial virus (RSV) remains a leading global cause of infant mortality and adult morbidity. Infection, which recurs throughout life, elicits only short-lived immunity. The development of a safe and efficacious vaccine has, thus far, been elusive. Recent technological advances, however, have yielded promising RSV vaccine candidates that are based on solving atomic-level structures of surface glycoproteins interacting with neutralizing antibodies. The class I fusion glycoprotein, F, serves as the primary antigenic component of most vaccines, and is the target of the only licensed monoclonal antibody product used to reduce the frequency of severe disease in high-risk neonates. However, success of prior F-based vaccines has been limited by the lack of understanding how the conformational rearrangement between a metastable prefusion F (pre-F) and a stable postfusion F (post-F) affected the epitope content. Neutralizing epitopes reside on both conformations, but those specific to pre-F are far more potent than those previously identified and present on post-F. The solution of the pre-F structure and its subsequent characterization and stabilization illustrates the value of a structure-based approach to vaccine development, and provides hope that a safe and effective RSV vaccine is possible. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
11. Stabilized coronavirus spike stem elicits a broadly protective antibody.
- Author
-
Hsieh, Ching-Lin, Werner, Anne P., Leist, Sarah R., Stevens, Laura J., Falconer, Ester, Goldsmith, Jory A., Chou, Chia-Wei, Abiona, Olubukola M., West, Ande, Westendorf, Kathryn, Muthuraman, Krithika, Fritch, Ethan J., Dinnon III, Kenneth H., Schäfer, Alexandra, Denison, Mark R., Chappell, James D., Baric, Ralph S., Graham, Barney S., Corbett, Kizzmekia S., and McLellan, Jason S.
- Abstract
Current coronavirus (CoV) vaccines primarily target immunodominant epitopes in the S1 subunit, which are poorly conserved and susceptible to escape mutations, thus threatening vaccine efficacy. Here, we use structure-guided protein engineering to remove the S1 subunit from the Middle East respiratory syndrome (MERS)-CoV spike (S) glycoprotein and develop stabilized stem (SS) antigens. Vaccination with MERS SS elicits cross-reactive β-CoV antibody responses and protects mice against lethal MERS-CoV challenge. High-throughput screening of antibody-secreting cells from MERS SS-immunized mice led to the discovery of a panel of cross-reactive monoclonal antibodies. Among them, antibody IgG22 binds with high affinity to both MERS-CoV and severe acute respiratory syndrome (SARS)-CoV-2 S proteins, and a combination of electron microscopy and crystal structures localizes the epitope to a conserved coiled-coil region in the S2 subunit. Passive transfer of IgG22 protects mice against both MERS-CoV and SARS-CoV-2 challenge. Collectively, these results provide a proof of principle for cross-reactive CoV antibodies and inform the development of pan-CoV vaccines and therapeutic antibodies. [Display omitted] • Structure-guided design generates MERS-CoV spike stabilized stem (SS) antigens • Cross-reactive CoV-spike-stem-specific monoclonal antibodies • Structures of the Fab22-spike complexes reveal a conserved, protective epitope • Passive transfer of IgG22 protects mice against MERS-CoV and SARS-CoV-2 challenge Hsieh et al. generate MERS-CoV spike stabilized stem (SS) antigens using a structure-guided approach. Mice immunized with MERS SS are protected against MERS-CoV challenge and used for isolation of cross-reactive monoclonal antibodies, including IgG22, which protects mice against MERS-CoV and SARS-CoV-2 challenges. Structures of Fab22-spike complexes reveal a conserved epitope. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
12. The histopathology of fatal untreated human respiratory syncytial virus infection.
- Author
-
Johnson, Joyce E, Gonzales, Ricardo A, Olson, Sandy J, Wright, Peter F, and Graham, Barney S
- Published
- 2007
- Full Text
- View/download PDF
13. Smallpox vaccines: Past, present, and future.
- Author
-
Parrino, Janie and Graham, Barney S.
- Subjects
SMALLPOX vaccines ,PREVENTIVE medicine ,VIRAL vaccines ,MEDICAL care - Abstract
The global eradication of smallpox was a tremendous achievement made possible by the development of an effective vaccine. Routine vaccination of the general population is no longer recommended. However, stocks of variola virus, the causative agent of smallpox, still exist in 2 secure laboratories, and permanent disposal has been controversial. In addition, there is speculation that variola virus may exist outside of these 2 facilities, and there is a concern that the threat of smallpox will be used as a bioterrorist weapon. In 2002, this concern led to a vaccination campaign in US military and civilian healthcare workers and first responders. Although the historical live virus vaccine has proven efficacy, it also is associated with serious adverse events and rare fatal reactions, particularly in the setting of immunodeficiency and atopic eczema. In addition, this vaccine was historically produced using animal intermediaries in a process that was prone to contamination and not acceptable for current manufacturing standards. Development of alternative poxvirus vaccines is focused on replication-defective viruses, gene-based vectors, and subunit approaches to improve safety and immunogenicity. The conundrum is that in the absence of an intentional release of variola, efficacy evaluation of new candidate vaccines will be limited to animal model testing, which creates new challenges for the vaccine licensure process. Although motivated by the threat of bioterrorism, the hope is for new poxvirus vaccines to have their greatest utility against other pathogenic orthopoxviruses such as monkeypox and for the development of recombinant poxvirus-based vectors to treat and prevent other diseases. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
14. Respiratory syncytial virus infection in the absence of STAT1 results in airway dysfunction, airway mucus, and augmented IL-17 levels.
- Author
-
Hashimoto, Koichi, Durbin, Joan E., Zhou, Weisong, Collins, Robert D., Ho, Samuel B., Kolls, Jay K., Dubin, Patricia J., Sheller, James R., Goleniewska, Kasia, O'Neal, Jamye F., Olson, Sandra J., Mitchell, Daphne, Graham, Barney S., and Peebles, R. Stokes
- Subjects
PARAMYXOVIRUSES ,RESPIRATORY syncytial virus ,VIRUS diseases ,CYTOKINES - Abstract
Background: Respiratory syncytial virus (RSV) is the leading infectious cause of respiratory failure and wheezing in infants and young children. Prematurity is the greatest risk factor for severe RSV-induced disease, and recent studies suggest that premature children have lower levels of the type I IFNs (α/β), for which signal transducer and activator of transcription (STAT) 1 is a critical intracellular signaling molecule. Objective: We hypothesized that RSV infection in STAT1 knockout (STAT1 KO) mice would result in both increased airway resistance and airway hyperresponsiveness. Methods: Wild-type (WT) and STAT1 KO mice on a BALB/c background were either RSV or mock infected. Phenotypic response to infection was assessed by means of plethysmography, immunohistochemistry, and lung cytokine measurement. Results: We found that STAT1 KO mice infected with RSV (STAT1 KO-RSV) had greater baseline lung resistance (P =.05) and airway responsiveness (P < .001) than mock-infected STAT1 KO (STAT1 KO-MOCK), RSV-infected wild type (WT-RSV), and mock-infected wild type (WT-MOCK) mice. In addition, the STAT1 KO-RSV mice showed induction of mucus production and expression of gob-5 and Muc5ac, conditions not present in any of the other 3 groups. IL-17, a cytokine that regulates Muc5ac expression, was expressed in the lungs of the STAT1 KO-RSV mice, whereas lung levels of IL-17 were undetectable in the remaining groups. Expression of the IL-23–specific p19 subunit was also increased in the STAT1 KO-RSV mice but not in the WT-RSV mice. Conclusion: These results show that STAT1 has an important regulatory role in RSV-induced alteration of airway function. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
15. Tribute to David T. Karzon, MD and Robert M. Chanock, MD
- Author
-
Graham, Barney S. and Crowe, Jr., James E.
- Published
- 2011
- Full Text
- View/download PDF
16. Structural Definition of a Neutralization-Sensitive Epitope on the MERS-CoV S1-NTD.
- Author
-
Wang, Nianshuang, Rosen, Osnat, Wang, Lingshu, Turner, Hannah L., Stevens, Laura J., Corbett, Kizzmekia S., Bowman, Charles A., Pallesen, Jesper, Shi, Wei, Zhang, Yi, Leung, Kwanyee, Kirchdoerfer, Robert N., Becker, Michelle M., Denison, Mark R., Chappell, James D., Ward, Andrew B., Graham, Barney S., and McLellan, Jason S.
- Abstract
Middle East respiratory syndrome coronavirus (MERS-CoV) emerged into the human population in 2012 and has caused substantial morbidity and mortality. Potently neutralizing antibodies targeting the receptor-binding domain (RBD) on MERS-CoV spike (S) protein have been characterized, but much less is known about antibodies targeting non-RBD epitopes. Here, we report the structural and functional characterization of G2, a neutralizing antibody targeting the MERS-CoV S1 N-terminal domain (S1-NTD). Structures of G2 alone and in complex with the MERS-CoV S1-NTD define a site of vulnerability comprising two loops, each of which contain a residue mutated in G2-escape variants. Cell-surface binding studies and in vitro competition experiments demonstrate that G2 strongly disrupts the attachment of MERS-CoV S to its receptor, dipeptidyl peptidase-4 (DPP4), with the inhibition requiring the native trimeric S conformation. These results advance our understanding of antibody-mediated neutralization of coronaviruses and should facilitate the development of immunotherapeutics and vaccines against MERS-CoV. • The epitope for the neutralizing antibody G2 is confined to the apex of the MERS-CoV S1-NTD • G2 epitope is relatively well conserved • G2 IgG and Fab both neutralize pseudotyped and authentic MERS-CoV • G2 neutralizes by preventing the binding of DPP4 to trimeric S protein Wang et al. report the structural and functional characterization of the Middle East respiratory syndrome coronavirus (MERS-CoV)-neutralizing antibody G2. G2 recognizes a conserved epitope on the MERS-CoV S1 N-terminal domain (S1-NTD) and neutralizes MERS-CoV by interfering with binding to host receptor dipeptidyl peptidase-4 (DPP4). The findings are relevant for understanding the viral attachment mechanism and for the development of S1-NTD-based vaccines. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
17. Human amniotic fluid antibodies protect the neonate against respiratory syncytial virus infection.
- Author
-
Jacobino, Shamir R., Nederend, Maaike, Hennus, Marije, Houben, Michiel L., Ngwuta, Joan O., Viveen, Marco, Coenjaerts, Frank E.J., Hack, C. Erik, van Neerven, R.J. Joost, Graham, Barney S., Bont, Louis, and Leusen, Jeanette H.W.
- Published
- 2016
- Full Text
- View/download PDF
18. VRC 311: Phase I Clinical Trial of a Virus-Like Particle Chikungunya Vaccine in Healthy Adults.
- Author
-
Chang, Lee-Jah, Mendoza, Floreliz, Saunders, Jamie, Plummer, Sarah, Yamshchikov, Galina V., Ledgerwood, Julie E., and Graham, Barney S.
- Published
- 2013
- Full Text
- View/download PDF
19. A multivalent polyomavirus vaccine elicits durable neutralizing antibody responses in macaques.
- Author
-
Peretti, Alberto, Scorpio, Diana G., Kong, Wing-Pui, Pang, Yuk-Ying S., McCarthy, Michael P., Ren, Kuishu, Jackson, Moriah, Graham, Barney S., Buck, Christopher B., McTamney, Patrick M., and Pastrana, Diana V.
- Subjects
- *
MACAQUES , *BK virus , *PAPILLOMAVIRUSES , *ANTIBODY formation , *POLYOMAVIRUSES , *HUMAN papillomavirus vaccines , *RHESUS monkeys , *VIRUS-like particles - Abstract
• Recombinant virus-like particle vaccine was safely administered to rhesus macaques. • Vaccination generated high-titer neutralizing antibody responses. • Multivalent BK/JC polyomavirus vaccine was as effective as monovalent vaccines. • High neutralizing titers were sustained for 92 weeks without appreciable decline. In 2019, there were about 100,000 kidney transplants globally, with more than a quarter of them performed in the United States. Unfortunately, some engrafted organs are lost to polyomavirus-associated nephropathy (PyVAN) caused by BK and JC viruses (BKPyV and JCPyV). Both viruses cause brain disease and possibly bladder cancer in immunosuppressed individuals. Transplant patients are routinely monitored for BKPyV viremia, which is an accepted hallmark of nascent nephropathy. If viremia is detected, a reduction in immunosuppressive therapy is standard care, but the intervention comes with increased risk of immune rejection of the engrafted organ. Recent reports have suggested that transplant recipients with high levels of polyomavirus-neutralizing antibodies are protected against PyVAN. Virus-like particle (VLP) vaccines, similar to approved human papillomavirus vaccines, have an excellent safety record and are known to induce high levels of neutralizing antibodies and long-lasting protection from infection. In this study, we demonstrate that VLPs representing BKPyV genotypes I, II, and IV, as well as JCPyV genotype 2 produced in insect cells elicit robust antibody titers. In rhesus macaques, all monkeys developed neutralizing antibody titers above a previously proposed protective threshold of 10,000. A second inoculation, administered 19 weeks after priming, boosted titers to a plateau of ≥ 25,000 that was maintained for almost two years. No vaccine-related adverse events were observed in any macaques. A multivalent BK/JC VLP immunogen did not show inferiority compared to the single-genotype VLP immunogens. Considering these encouraging results, we believe a clinical trial administering the multivalent VLP vaccine in patients waiting to receive a kidney transplant is warranted to evaluate its ability to reduce or eliminate PyVAN. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
20. Whither monkeypox vaccination
- Author
-
Rimoin, Anne W. and Graham, Barney S.
- Subjects
- *
MONKEYPOX , *ORTHOPOXVIRUSES , *IMMUNIZATION , *CLINICAL trials , *POXVIRUS diseases - Abstract
Abstract: Monkeypox (MPX) is a virulent orthopoxvirus that is endemic in some regions of Central Africa. MPX incidence has been rising since the cessation of routine smallpox immunization. While it causes significant disease, there is limited person-to-person spread, the incidence is still relatively low, and cases are generally restricted to remote areas that are difficult to access. Therefore, initiating vaccine trials or implementing vaccination programs would be challenging. This paper considers the factors that may influence future decisions on whether MPX vaccination should be pursued. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
21. Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape.
- Author
-
Mazur, Natalie I, Terstappen, Jonne, Baral, Ranju, Bardají, Azucena, Beutels, Philippe, Buchholz, Ursula J, Cohen, Cheryl, Crowe, James E, Cutland, Clare L, Eckert, Linda, Feikin, Daniel, Fitzpatrick, Tiffany, Fong, Youyi, Graham, Barney S, Heikkinen, Terho, Higgins, Deborah, Hirve, Siddhivinayak, Klugman, Keith P, Kragten-Tabatabaie, Leyla, and Lemey, Philippe
- Subjects
- *
RESPIRATORY syncytial virus , *MONOCLONAL antibodies , *CLINICAL trials , *VIRAL vaccines , *OLDER people - Abstract
Respiratory syncytial virus is the second most common cause of infant mortality and a major cause of morbidity and mortality in older adults (aged >60 years). Efforts to develop a respiratory syncytial virus vaccine or immunoprophylaxis remain highly active. 33 respiratory syncytial virus prevention candidates are in clinical development using six different approaches: recombinant vector, subunit, particle-based, live attenuated, chimeric, and nucleic acid vaccines; and monoclonal antibodies. Nine candidates are in phase 3 clinical trials. Understanding the epitopes targeted by highly neutralising antibodies has resulted in a shift from empirical to rational and structure-based vaccine and monoclonal antibody design. An extended half-life monoclonal antibody for all infants is likely to be within 1 year of regulatory approval (from August, 2022) for high-income countries. Live-attenuated vaccines are in development for older infants (aged >6 months). Subunit vaccines are in late-stage trials for pregnant women to protect infants, whereas vector, subunit, and nucleic acid approaches are being developed for older adults. Urgent next steps include ensuring access and affordability of a respiratory syncytial virus vaccine globally. This review gives an overview of respiratory syncytial virus vaccines and monoclonal antibodies in clinical development highlighting different target populations, antigens, and trial results. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
22. WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants – Key considerations for global use.
- Author
-
Sparrow, Erin, Adetifa, Ifedayo, Chaiyakunapruk, Nathorn, Cherian, Thomas, Fell, Deshayne B., Graham, Barney S., Innis, Bruce, Kaslow, David C., Karron, Ruth A., Nair, Harish, Neuzil, Kathleen M., Saha, Samir, Smith, Peter G., Srikantiah, Padmini, Were, Fred, Zar, Heather J., and Feikin, Daniel
- Subjects
- *
RESPIRATORY syncytial virus , *PRODUCT attributes , *MONOCLONAL antibodies , *INFANT diseases , *IMMUNIZATION , *MIDDLE-income countries - Abstract
World Health Organization (WHO) preferred product characteristics describe preferences for product attributes that would help optimize value and use to address global public health needs, with a particular focus on low- and middle-income countries. Having previously published preferred product characteristics for both maternal and paediatric respiratory syncytial virus (RSV) vaccines, WHO recently published preferred product characteristics for monoclonal antibodies to prevent severe RSV disease in infants. This article summarizes the key attributes from the preferred product characteristics and discusses key considerations for future access and use of preventive RSV monoclonal antibodies. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
23. Functional reconstitution of the MERS CoV receptor binding motif.
- Author
-
Uppalapati, Lakshminarasaiah, Roitburd-Berman, Anna, Weiss-Ottolenghi, Yael, Graham, Barney S., Dimitrov, Dimiter S., Ying, Tianlei, Failayev, Hila, Tsfadia, Yossi, and Gershoni, Jonathan M.
- Subjects
- *
MIDDLE East respiratory syndrome , *COVID-19 , *SARS-CoV-2 Omicron variant , *MERS coronavirus , *MONOCLONAL antibodies , *RESPIRATORY diseases , *DEATH rate - Abstract
In the early 1960's the first human coronaviruses (designated 229E and OC43) were identified as etiologic agents of the common cold, to be followed by the subsequent isolation of three more human coronaviruses similarly associated with cold-like diseases. In contrast to these "mild" coronaviruses, over the last 20 years there have been three independent events of emergence of pandemic severe and acute life-threatening respiratory diseases caused by three novel beta-coronaviruses, SARS CoV, MERS CoV and most recently SARS CoV2. Whereas the first SARS CoV appeared in November 2002 and spontaneously disappeared by the summer of 2003, MERS CoV has continued persistently to spill over to humans via an intermediary camel vector, causing tens of cases annually. Although human-to-human transmission is rare, the fatality rate of MERS CoV disease is remarkably higher than 30%. COVID-19 however, is fortunately much less fatal, despite that its etiologic agent, SARS CoV2, is tremendously infectious, particularly with the recent evolution of the Omicron variants of concern (BA.1 and BA.2). Of note, MERS CoV prevalence in camel populations in Africa and the Middle East is extremely high. Moreover, MERS CoV and SARS CoV2 co-exist in the Middle East and especially in Saudi Arabia and the UAE, where sporadic incidences of co-infection have already been reported. Co-infection, either due to reverse spill-over of SARS CoV2 to camels or in double infected humans could lead to recombination between the two viruses, rendering either SARS CoV2 more lethal or MERS CoV more transmittable. In an attempt to prepare for what could develop into a catastrophic event, we have focused on developing a novel epitope-based immunogen for MERS CoV. Implementing combinatorial phage-display conformer libraries, the Receptor Binding Motif (RBM) of the MERS CoV Spike protein has been successfully reconstituted and shown to be recognized by a panel of seven neutralizing monoclonal antibodies. • Reconstitution of the major neutralizing surface of the beta coronavirus MERS CoV. • Phage-display conformer libraries screened with neutralizing monoclonal antibodies. • Receptor Binding Motifs of coronaviruses as epitope-based immunogens. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
24. Genetic Vaccine for Respiratory Syncytial Virus Provides Protection Without Disease Potentiation.
- Author
-
Johnson, Teresa R, Rangel, David, Graham, Barney S, Brough, Douglas E, and Gall, Jason G
- Subjects
- *
RESPIRATORY syncytial virus , *IMMUNE response , *ADENOVIRUSES , *GLYCOPROTEINS , *T cells , *CYTOKINES , *IMMUNOPATHOLOGY - Abstract
Respiratory syncytial virus (RSV) is a major cause of infectious lower respiratory disease in infants and the elderly. As there is no vaccine for RSV, we developed a genetic vaccine approach that induced protection of the entire respiratory tract from a single parenteral administration. The approach was based on adenovirus vectors derived from newly isolated nonhuman primate viruses with low seroprevalence. We show for the first time that a single intramuscular (IM) injection of the replication-deficient adenovirus vectors expressing the RSV fusion (F0) glycoprotein induced immune responses that protected both the lungs and noses of cotton rats and mice even at low doses and for several months postimmunization. The immune response included high titers of neutralizing antibody that were maintained ≥24 weeks and RSV-specific CD8+ and CD4+ T cells. The vectors were as potently immunogenic as a human adenovirus 5 vector in these two key respiratory pathogen animal models. Importantly, there was minimal alveolitis and granulocytic infiltrates in the lung, and type 2 cytokines were not produced after RSV challenge even under conditions of partial protection. Overall, this genetic vaccine is highly effective without potentiating immunopathology, and the results support development of the vaccine candidate for human testing. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
25. Antibody levels against respiratory syncytial virus fusion protein conformations and lack of association with life-threatening infection in previously healthy infants.
- Author
-
Bonnin, Florencia A., Talarico, Laura B., Ferolla, Fausto M., Acosta, Patricio L., Phung, Emily, Kumar, Azad, Toledano, Analía, Caratozzolo, Ana, Neira, Pablo, Mascardi, Normando, Satragno, Daniela, Contrini, María M., Graham, Barney S., Ruckwardt, Tracy J., and López, Eduardo L.
- Subjects
- *
RESPIRATORY syncytial virus infections , *ANTIBODY titer , *CHIMERIC proteins , *RESPIRATORY syncytial virus , *VIRAL proteins - Abstract
• RSV F-specific antibodies did not correlate with protection against life-threatening RSV disease in infants. • Pre-existing acute RSV neutralizing antibodies did not correlate with protection against life-threatening RSV disease. • Acute RSV F-specific antibodies negatively correlated with patient age. • Convalescent RSV F-specific antibodies positively correlated with patient age for children over 2 months of age. • Acute RSV antibody titers showed no association with nasal RSV load. Humoral immune response against the pre-fusion (pre-F) conformation of respiratory syncytial virus (RSV) F protein has been proposed to play a protective role against infection. An RSV pre-F maternal vaccine has been recently approved in several countries to protect young infants against RSV. We aimed to assess serum IgG titers against the pre-F and post-F conformations of RSV F protein and their association with life-threatening RSV disease (LTD) in previously healthy infants. A prospective cohort study including hospitalized infants <12 months with a first RSV infection was conducted during 2017–2019. Patients with LTD required intensive care and mechanical respiratory assistance. RSV pre-F exclusive and post-F antibody responses were determined by post-F competition and non-competition immunoassays, respectively, and neutralizing activity was measured by plaque reduction neutralization test. Fifty-eight patients were included; the median age was 3.5 months and 41 % were females. Fifteen patients developed LTD. RSV F-specific antibody titers positively correlated with neutralizing antibody titers in acute and convalescent phases but, importantly, they did not associate with LTD. Acute RSV pre-F exclusive and post-F IgG titers negatively correlated with patient age (P = 0.0007 and P < 0.0001), while a positive correlation was observed between the fold changes in RSV F-specific antibody titers between convalescent and acute phase and patient age (P = 0.0014 and P < 0.0001). Infants ≤2 months exhibited significantly lower fold-changes in RSV F-specific and neutralizing antibody titers between convalescence and acute phase than older infants. Additionally, acute RSV antibody titers showed no correlation with nasal RSV load and, furthermore, nasal viral load was not associated with the development of LTD. This study highlights that protection against life-threatening RSV disease is not necessarily antibody-dependent. Further characterization of the immune response against RSV and its role in protection against severe disease is important for the development of the safest possible preventive strategies. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
26. Level of maternal respiratory syncytial virus (RSV) F antibodies in hospitalized children and correlates of protection.
- Author
-
Taleb, Sara A., Al-Ansari, Khalid, Nasrallah, Gheyath K., Elrayess, Mohamed A., Al-Thani, Asmaa A., Derrien-Colemyn, Alexandrine, Ruckwardt, Tracy J., Graham, Barney S., and Yassine, Hadi M.
- Subjects
- *
CHILD welfare , *HOSPITAL care of children , *RESPIRATORY syncytial virus , *RESPIRATORY infections in children , *IMMUNOGLOBULINS - Abstract
• This study found that 14% of maternal antibodies were present in infants at hospitalization. • An average log 2 EP titer of 10.2 was directed to both F-protein conformations. • The neutralizing activity in infants was greater than that of binding antibodies. • One-third of infants had relatively high NAb titers, yet, they were hospitalized. Respiratory syncytial virus (RSV) is a major cause of lower respiratory infection among children and no vaccine is available. The stabilized form of the fusion (F) protein – pre-F – is a leading vaccine candidate to target different populations, including pregnant women. This study aimed to determine the magnitude and nature of RSV-directed maternal antibodies (matAbs) in hospitalized children with RSV infection. Sixty-five paired blood samples were collected from RSV-infected children aged <6 months and their corresponding mothers. All pairs were screened for levels of pre-F and post-F antibodies using ELISA. The neutralizing antibodies (NAbs) in both groups were measured in vitro against mKate RSV-A2 using H28 cells. It was found that 14% of matAbs (log 2 12.8) were present in infants at hospitalization, with an average log 2 EP titer of 10.2 directed to both F-protein conformations. Additionally, 61.4% of maternal NAbs (log 2 EC 50 = 9.4) were detected in infants (log 2 EC 50 = 8.7), which were mostly pre-F exclusive (81%). Pre-F antibodies in children showed a positive correlation with matAbs titers and negative correlations with age and bronchiolitis score. The maintenance of neutralizing activity in infants relative to maternal titers was greater than the maintenance of antibody binding based on ELISA, suggesting that higher-potency antibodies may have a longer half-life than weakly neutralizing antibodies. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
27. Vaccine-associated enhanced disease: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data.
- Author
-
Munoz, Flor M., Cramer, Jakob P., Dekker, Cornelia L., Dudley, Matthew Z., Graham, Barney S., Gurwith, Marc, Law, Barbara, Perlman, Stanley, Polack, Fernando P., Spergel, Jonathan M., Van Braeckel, Eva, Ward, Brian J., Didierlaurent, Arnaud M., and Lambert, Paul Henri
- Subjects
- *
ACQUISITION of data , *VACCINE development , *IMMUNIZATION , *DEFINITIONS , *SARS-CoV-2 , *VACCINES - Abstract
This is a Brighton Collaboration Case Definition of the term "Vaccine Associated Enhanced Disease" to be utilized in the evaluation of adverse events following immunization. The Case Definition was developed by a group of experts convened by the Coalition for Epidemic Preparedness Innovations (CEPI) in the context of active development of vaccines for SARS-CoV-2 vaccines and other emerging pathogens. The case definition format of the Brighton Collaboration was followed to develop a consensus definition and defined levels of certainty, after an exhaustive review of the literature and expert consultation. The document underwent peer review by the Brighton Collaboration Network and by selected Expert Reviewers prior to submission. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
28. Consensus summary report for CEPI/BC March 12–13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.
- Author
-
Lambert, Paul-Henri, Ambrosino, Donna M., Andersen, Svein R., Baric, Ralph S., Black, Steven B., Chen, Robert T., Dekker, Cornelia L., Didierlaurent, Arnaud M., Graham, Barney S., Martin, Samantha D., Molrine, Deborah C., Perlman, Stanley, Picard-Fraser, Philip A., Pollard, Andrew J., Qin, Chuan, Subbarao, Kanta, and Cramer, Jakob P.
- Subjects
- *
SARS disease , *COVID-19 , *MIDDLE East respiratory syndrome , *SARS-CoV-2 , *RISK assessment , *RESPIRATORY syncytial virus , *COVID-19 vaccines - Abstract
A novel coronavirus (CoV), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in late 2019 in Wuhan, China and has since spread as a global pandemic. Safe and effective vaccines are thus urgently needed to reduce the significant morbidity and mortality of Coronavirus Disease 2019 (COVID-19) disease and ease the major economic impact. There has been an unprecedented rapid response by vaccine developers with now over one hundred vaccine candidates in development and at least six having reached clinical trials. However, a major challenge during rapid development is to avoid safety issues both by thoughtful vaccine design and by thorough evaluation in a timely manner. A syndrome of "disease enhancement" has been reported in the past for a few viral vaccines where those immunized suffered increased severity or death when they later encountered the virus or were found to have an increased frequency of infection. Animal models allowed scientists to determine the underlying mechanism for the former in the case of Respiratory syncytial virus (RSV) vaccine and have been utilized to design and screen new RSV vaccine candidates. Because some Middle East respiratory syndrome (MERS) and SARS-CoV-1 vaccines have shown evidence of disease enhancement in some animal models, this is a particular concern for SARS-CoV-2 vaccines. To address this challenge, the Coalition for Epidemic Preparedness Innovations (CEPI) and the Brighton Collaboration (BC) Safety Platform for Emergency vACcines (SPEAC) convened a scientific working meeting on March 12 and 13, 2020 of experts in the field of vaccine immunology and coronaviruses to consider what vaccine designs could reduce safety concerns and how animal models and immunological assessments in early clinical trials can help to assess the risk. This report summarizes the evidence presented and provides considerations for safety assessment of COVID-19 vaccine candidates in accelerated vaccine development. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
29. Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study.
- Author
-
De Santis, Olga, Audran, Régine, Pothin, Emilie, Warpelin-Decrausaz, Loane, Vallotton, Laure, Wuerzner, Grégoire, Cochet, Camille, Estoppey, Daniel, Steiner-Monard, Viviane, Lonchampt, Sophie, Thierry, Anne-Christine, Mayor, Carole, Bailer, Robert T, Mbaya, Olivier Tshiani, Zhou, Yan, Ploquin, Aurélie, Sullivan, Nancy J, Graham, Barney S, Roman, François, and De Ryck, Iris
- Subjects
- *
EBOLA virus disease vaccines , *ADENOVIRUSES , *VACCINE safety , *GENETIC vectors , *PLACEBOS , *RANDOMIZED controlled trials , *EBOLA virus disease prevention , *CLASSIFICATION of viruses , *CLINICAL trials , *COMPARATIVE studies , *EBOLA virus disease , *FEVER , *IMMUNITY , *IMMUNOGLOBULINS , *RESEARCH methodology , *MEDICAL cooperation , *RESEARCH , *RESEARCH funding , *MILITARY personnel , *VACCINES , *VIRAL antibodies , *VIRAL vaccines , *EVALUATION research , *EBOLA virus - Abstract
Background: The ongoing Ebola outbreak led to accelerated efforts to test vaccine candidates. On the basis of a request by WHO, we aimed to assess the safety and immunogenicity of the monovalent, recombinant, chimpanzee adenovirus type-3 vector-based Ebola Zaire vaccine (ChAd3-EBO-Z).Methods: We did this randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a trial at the Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. Participants (aged 18-65 years) were randomly assigned (2:2:1), via two computer-generated randomisation lists for individuals potentially deployed in endemic areas and those not deployed, to receive a single intramuscular dose of high-dose vaccine (5 × 10(10) viral particles), low-dose vaccine (2·5 × 10(10) viral particles), or placebo. Deployed participants were allocated to only the vaccine groups. Group allocation was concealed from non-deployed participants, investigators, and outcome assessors. The safety evaluation was not masked for potentially deployed participants, who were therefore not included in the safety analysis for comparison between the vaccine doses and placebo, but were pooled with the non-deployed group to compare immunogenicity. The main objectives were safety and immunogenicity of ChAd3-EBO-Z. We did analysis by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT02289027.Findings: Between Oct 24, 2014, and June 22, 2015, we randomly assigned 120 participants, of whom 18 (15%) were potentially deployed and 102 (85%) were non-deployed, to receive high-dose vaccine (n=49), low-dose vaccine (n=51), or placebo (n=20). Participants were followed up for 6 months. No vaccine-related serious adverse events were reported. We recorded local adverse events in 30 (75%) of 40 participants in the high-dose group, 33 (79%) of 42 participants in the low-dose group, and five (25%) of 20 participants in the placebo group. Fatigue or malaise was the most common systemic adverse event, reported in 25 (62%) participants in the high-dose group, 25 (60%) participants in the low-dose group, and five (25%) participants in the placebo group, followed by headache, reported in 23 (57%), 25 (60%), and three (15%) participants, respectively. Fever occurred 24 h after injection in 12 (30%) participants in the high-dose group and 11 (26%) participants in the low-dose group versus one (5%) participant in the placebo group. Geometric mean concentrations of IgG antibodies against Ebola glycoprotein peaked on day 28 at 51 μg/mL (95% CI 41·1-63·3) in the high-dose group, 44·9 μg/mL (25·8-56·3) in the low-dose group, and 5·2 μg/mL (3·5-7·6) in the placebo group, with respective response rates of 96% (95% CI 85·7-99·5), 96% (86·5-99·5), and 5% (0·1-24·9). Geometric mean concentrations decreased by day 180 to 25·5 μg/mL (95% CI 20·6-31·5) in the high-dose group, 22·1 μg/mL (19·3-28·6) in the low-dose group, and 3·2 μg/mL (2·4-4·9) in the placebo group. 28 (57%) participants given high-dose vaccine and 31 (61%) participants given low-dose vaccine developed glycoprotein-specific CD4 cell responses, and 33 (67%) and 35 (69%), respectively, developed CD8 responses.Interpretation: ChAd3-EBO-Z was safe and well tolerated, although mild to moderate systemic adverse events were common. A single dose was immunogenic in almost all vaccine recipients. Antibody responses were still significantly present at 6 months. There was no significant difference between doses for safety and immunogenicity outcomes. This acceptable safety profile provides a reliable basis to proceed with phase 2 and phase 3 efficacy trials in Africa.Funding: Swiss State Secretariat for Education, Research and Innovation (SERI), through the EU Horizon 2020 Research and Innovation Programme. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
30. Phase I clinical evaluation of seasonal influenza hemagglutinin (HA) DNA vaccine prime followed by trivalent influenza inactivated vaccine (IIV3) boost.
- Author
-
Ledgerwood, Julie E., Hu, Zonghui, Costner, Pamela, Yamshchikov, Galina, Enama, Mary E., Plummer, Sarah, Hendel, Cynthia S., Holman, Lasonji, Larkin, Brenda, Gordon, Ingelise, Bailer, Robert T., Poretz, Donald M., Sarwar, Uzma, Kabadi, Alisha, Koup, Richard, Mascola, John R., and Graham, Barney S.
- Subjects
- *
SEASONAL influenza , *HEMAGGLUTININ , *IMMUNE response , *DNA vaccines , *IMMUNOGENETICS , *DNA primers , *PREVENTION - Abstract
Annual influenza vaccination reduces the risks of influenza when the vaccines are well matched to circulating strains, but development of an approach that induces broader and more durable immune responses would be beneficial. We conducted two companion Phase 1 studies, VRC 307 and VRC 309, over sequential seasons (2008–2009 and 2009–2010) in which only the influenza B strain component of the vaccines differed. Objectives were safety and immunogenicity of prime–boost vaccination schedules. A schedule of DNA vaccine encoding for seasonal influenza hemagglutinins (HA) prime followed by seasonal trivalent influenza inactivated vaccine (IIV3) boost (HA DNA–IIV3) was compared to placebo (PBS)–IIV3 or IIV3–IIV3. Cumulatively, 111 adults were randomized to HA DNA–IIV3 (n = 66), PBS–IIV3 (n = 25) or IIV3–IIV3 (n = 20). Safety was assessed by clinical observations, laboratory parameters and 7-day solicited reactogenicity. The seasonal HA DNA prime–IIV3 boost regimen was evaluated as safe and well tolerated. There were no serious adverse events. The local and systemic reactogenicity for HA DNA, IIV and placebo were reported predominantly as none or mild within the first 5 days post-vaccination. There was no significant difference in immunogenicity detected between the treatment groups as evaluated by hemagglutination inhibition (HAI) assay. The studies demonstrated the safety and immunogenicity of seasonal HA DNA–IIV3 regimen, but the 3–4 week prime–boost interval was suboptimal for improving influenza-specific immune responses. This is consistent with observations in avian H5 DNA vaccine prime–boost studies in which a long interval, but not a short interval, was associated with improved immunogenicity. Trial Registration: NCT00858611 for VRC 307 and NCT00995982 for VRC 309. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
31. DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials
- Author
-
Ledgerwood, Julie E, Wei, Chih-Jen, Hu, Zonghui, Gordon, Ingelise J, Enama, Mary E, Hendel, Cynthia S, McTamney, Patrick M, Pearce, Melissa B, Yassine, Hadi M, Boyington, Jeffrey C, Bailer, Robert, Tumpey, Terrence M, Koup, Richard A, Mascola, John R, Nabel, Gary J, and Graham, Barney S
- Subjects
- *
INFLUENZA vaccines , *IMMUNE response , *DNA , *VIRAL antibodies , *CLINICAL trials , *IMMUNOASSAY , *CYTOKINES - Abstract
Summary: Background: Because the general population is largely naive to H5N1 influenza, antibodies generated to H5 allow analysis of novel influenza vaccines independent of background immunity from previous infection. We assessed the safety and immunogenicity of DNA encoding H5 as a priming vaccine to improve antibody responses to inactivated influenza vaccination. Methods: In VRC 306 and VRC 310, two sequentially enrolled phase 1, open-label, randomised clinical trials, healthy adults (age 18–60 years) were randomly assigned to receive intramuscular H5 DNA (4 mg) at day 0 or twice, at day 0 and week 4, followed by H5N1 monovalent inactivated vaccine (MIV; 90 μg) at 4 or 24 weeks, and compared with a two-dose regimen of H5N1 MIV with either a 4 or 24 week interval. Antibody responses were assessed by haemagglutination inhibition (HAI), ELISA, neutralisation (ID80), and immunoassays for stem-directed antibodies. T cell responses were assessed by intracellular cytokine staining. After enrolment, investigators and individuals were not masked to group assignment. VRC 306 and VRC 310 are registered with ClinicalTrials.gov, numbers NCT00776711 and NCT01086657, respectively. Findings: In VRC 306, 60 individuals were randomly assigned to the four groups (15 in each) and 59 received the vaccinations. In VRC 310, of the 21 individuals enrolled, 20 received the vaccinations (nine received a two-dose regimen of H5N1 MIV and 11 received H5 DNA at day 0 followed by H5N1 MIV at week 24). H5 DNA priming was safe and enhanced H5-specific antibody titres following an H5N1 MIV boost, especially when the interval between DNA prime and MIV boost was extended to 24 weeks. In the two studies, DNA priming with a 24-week MIV boost interval induced protective HAI titres in 21 (81%) of 26 of individuals, with an increase in geometric mean titre (GMT) of more than four times that of individuals given the MIV-MIV regimen at 4 or 24 weeks (GMT 103–206 vs GMT 27–33). Additionally, neutralising antibodies directed to the conserved stem region of H5 were induced by this prime-boost regimen in several individuals. No vaccine-related serious adverse events were recorded. Interpretation: DNA priming 24 weeks in advance of influenza vaccine boosting increased the magnitude of protective antibody responses (HAI) and in some cases induced haemagglutinin-stem-specific neutralising antibodies. A DNA-MIV vaccine regimen could enhance the efficacy of H5 or other influenza vaccines and shows that anti-stem antibodies can be elicited by vaccination in man. Funding: National Institutes of Health. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
32. T Cell Receptor Clonotype Influences Epitope Hierarchy in the CD8+ T Cell Response to Respiratory Syncytial Virus Infection.
- Author
-
Billam, Padma, Bonaparte, Kathryn L., Jie Liu, Ruckwardt, Tracy J., Man Chen, Ryder, Alex B., Rui Wang, Dash, Pradyot, Thomas, Paul G., and Graham, Barney S.
- Subjects
- *
BIOCHEMICAL research , *EPITOPES , *T cell receptors , *LYMPHOCYTES , *PARAMYXOVIRUSES , *CELL membranes - Abstract
CD8+ T cell responses are important for recognizing and resolving viral infections. To better understand the selection and hierarchy of virus-specific T cell responses, we compared the T cell receptor (TCR) clonotype in parent and hybrid strains of respiratory syncytial virus-infected mice. KdM282-90 (SYIGSINNI) in BALB/c and DbM187-195 (NAITNAKII) in C57Bl/6 are both dominant epitopes in parent strains but assume a distinct hierarchy, with KdM282-90 dominant to DbM187-195 in hybrid CB6F1/J mice. The dominant KdM282-90 response is relatively public and is restricted primarily to the highly prevalent Vβ13.2 in BALB/c and hybrid mice, whereas DbM187-195 responses in C57BL/6 mice are relatively private and involve multiple Vβ subtypes, some of which are lost in hybrids. A significant frequency of TCR CDR3 sequences in the DbM187-195 response have a distinct "(D/E)WG" motif formed by a limited number of recombination strategies. Modeling of the dominant epitope suggested a flat, featureless structure, but DbM187-195 showed a distinctive structure formed by Lys7. The data suggest that common recombination events in prevalent Vβ genes may provide a numerical advantage in the T cell response and that distinct epitope structures may impose more limited options for successful TCR selection. Defining how epitope structure is interpreted to inform T cell function will improve the design of future gene-based vaccines. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
33. TLR9 agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapy during primary RSV infection increases disease severity
- Author
-
Johnson, Teresa R., Rao, Srinivas, Seder, Robert A., Chen, Man, and Graham, Barney S.
- Subjects
- *
VIRAL vaccines , *RESPIRATORY syncytial virus , *IMMUNOLOGICAL adjuvants , *LABORATORY mice , *ANIMAL disease models , *IMMUNOGENETICS , *BINDING sites , *IMMUNIZATION , *IMMUNE response - Abstract
Abstract: Agonists for TLR7, TLR8, and TLR9 have been shown to enhance vaccine immunogenicity. We evaluated the impact of TLR activation on RSV disease in a murine model by administering TLR7/8 and TLR9 agonists during FI-RSV immunization or RSV infection. CpG administered during immunization reduced disease following challenge as evidenced by decreased lung pathology, illness, and cytokines. In marked contrast, TLR7/8 agonist had little impact. To evaluate potential therapeutic use, TLR agonists were administered during primary infection. Although type 2 cytokine responses decreased and type 1 cytokines and MIP-1-α/β increased, both TLR7/8 and TLR9 agonists increased clinical symptoms and pulmonary inflammation when administered during primary infection. Thus, TLR9-induced signaling during FI-RSV immunization reduced vaccine-enhanced disease whereas immunostimulatory properties of TLR agonists enhanced disease severity when used during RSV infection. Immunomodulation elicited by TLR9 agonist confirms the adjuvant potential of TLR agonists during RSV immunization. However, in contrast to work done with HIV-1 vaccines, the inability of TLR7/8 agonist to boost type 1 vaccine-induced RSV immunity demonstrates pathogen–TLR specificity. These data reveal that the timing of administration of immunomodulatory agents is critical. Furthermore, these data underscore that amplification of anti-viral immune responses may result in immunopathology rather than immune-mediated protection. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
34. A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial
- Author
-
Martin, Julie E., Louder, Mark K., Holman, LaSonji A., Gordon, Ingelise J., Enama, Mary E., Larkin, Brenda D., Andrews, Charla A., Vogel, Leatrice, Koup, Richard A., Roederer, Mario, Bailer, Robert T., Gomez, Phillip L., Nason, Martha, Mascola, John R., Nabel, Gary J., and Graham, Barney S.
- Subjects
- *
SARS disease , *DNA vaccines , *CORONAVIRUSES , *IMMUNOGLOBULINS , *CELLULAR immunity , *IMMUNE response , *COMMUNICABLE diseases , *CLINICAL trials , *VACCINATION - Abstract
Abstract: Background: The severe acute respiratory syndrome (SARS) virus is a member of the Coronaviridae (CoV) family that first appeared in the Guangdong Province of China in 2002 and was recognized as an emerging infectious disease in March 2003. Over 8000 cases and 900 deaths occurred during the epidemic. We report the safety and immunogenicity of a SARS DNA vaccine in a Phase I human study. Methods: A single-plasmid DNA vaccine encoding the Spike (S) glycoprotein was evaluated in 10 healthy adults. Nine subjects completed the 3 dose vaccination schedule and were evaluated for vaccine safety and immune responses. Immune response was assessed by intracellular cytokine staining (ICS), ELISpot, ELISA, and neutralization assays. Results: The vaccine was well tolerated. SARS-CoV-specific antibody was detected by ELISA in 8 of 10 subjects and neutralizing antibody was detected in all subjects who received 3 doses of vaccine. SARS-CoV-specific CD4+ T-cell responses were detected in all vaccinees, and CD8+ T-cell responses in ∼20% of individuals. Conclusions: The VRC SARS DNA vaccine was well tolerated and produced cellular immune responses and neutralizing antibody in healthy adults. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
35. Induction of HIV-specific functional immune responses by a multiclade HIV-1 DNA vaccine candidate in healthy Ugandans
- Author
-
Eller, Michael A., Eller, Leigh Anne, Opollo, Marc S., Ouma, Benson J., Oballah, Peter O., Galley, Lynee, Karnasuta, Chitraporn, Kim, Silvia Ratto, Robb, Merlin L., Michael, Nelson L., Kibuuka, Hannah, Wabwire-Mangen, Fred, Graham, Barney S., Birx, Deborah L., de Souza, Mark S., and Cox, Josephine H.
- Subjects
- *
IMMUNE response , *HIV infections , *DNA vaccines , *UGANDANS - Abstract
Abstract: A phase I randomized, double blind, placebo-controlled trial to assess the immunogenicity of a multiclade HIV-1 DNA plasmid vaccine was conducted in 31 HIV-1-negative Ugandans. Following immunization with DNA at 0, 1, and 2 months, the frequency of HIV-specific immune responses was assessed up to 10 months using a standard chromium release assay (CRA), lymphoproliferative assay (LPA), and antibody dependent cell-mediated cytotoxicity assay (ADCC). Seven of 15 (47%) vaccinees demonstrated CTL activity using the CRA to HIV-1 Env B with responses observed 1 month following the second vaccination and as late as 7 months following complete immunization. Additionally, lymphoproliferative reponses were observed in 14/15 vaccinees against p24. No CTL or LPA responses were observed at baseline or in the placebo group. ADCC activity was minimally induced by DNA vaccination. This study demonstrates that immunization with DNA alone induces CTL and lymphoproliferative responses in a population that will participate in a phase IIb study evaluating HIV-1 DNA priming followed by boosting with a replication-defective recombinant adenovirus vector. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
36. Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine
- Author
-
Catanzaro, Andrew T., Roederer, Mario, Koup, Richard A., Bailer, Robert T., Enama, Mary E., Nason, Martha C., Martin, Julie E., Rucker, Steve, Andrews, Charla A., Gomez, Phillip L., Mascola, John R., Nabel, Gary J., and Graham, Barney S.
- Subjects
- *
DNA vaccines , *HIV , *T cells , *VACCINATION - Abstract
Abstract: Needle-free delivery of a six-plasmid HIV-1 DNA vaccine encoding EnvA, EnvB, EnvC, and subtype B Gag, Pol, and Nef underwent open-label evaluation in 15 subjects; 14 completed the 0, 1, 2 month vaccination schedule. T cell responses to HIV-specific peptide pools were detected by intracellular cytokine staining of CD4+ [13/14 (93%)] and CD8+ [5/14 (36%)], and by ELISpot in 11/14 (79%). Ten of 14 (71%) had ELISA antibody responses to Env proteins. Compared to a four-plasmid product, Gag- and Nef-specific T cell responses were improved, while Env-specific responses were maintained. This candidate vaccine has now advanced to Phase II evaluation. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
37. Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax® challenge in vaccinia-naïve and vaccinia-immune individuals
- Author
-
Parrino, Janie, McCurdy, Lewis H., Larkin, Brenda D., Gordon, Ingelise J., Rucker, Steven E., Enama, Mary E., Koup, Richard A., Roederer, Mario, Bailer, Robert T., Moodie, Zoe, Gu, Lin, Yan, Lihan, and Graham, Barney S.
- Subjects
- *
VACCINIA , *VACCINATION , *T cells , *IMMUNE response , *ORTHOPOXVIRUSES - Abstract
Abstract: Modified vaccinia Ankara (MVA) was evaluated as an alternative to Dryvax® in vaccinia-naïve and vaccinia-immune adult volunteers. Subjects received intramuscular MVA or placebo followed by Dryvax® challenge at 3 months. Two or more doses of MVA prior to Dryvax® reduced severity of lesion formation, decreased magnitude and duration of viral shedding, and augmented post-Dryvax® vaccinia-specific CD8+ T cell responses and extracellular enveloped virus protein-specific antibody responses. MVA vaccination is safe and immunogenic and improves the safety and immunogenicity of subsequent Dryvax® vaccination supporting the potential for using MVA as a vaccine in the general population to improve immunity to orthopoxviruses. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
38. IL-13 is associated with reduced illness and replication in primary respiratory syncytial virus infection in the mouse
- Author
-
Zhou, Weisong, Hashimoto, Koichi, Moore, Martin L., Elias, Jack A., Zhu, Zhou, Durbin, Joan, Colasurdo, Giuseppe, Rutigliano, John A., Chiappetta, Constance L., Goleniewska, Kasia, O'Neal, Jamye F., Graham, Barney S., and Stokes Peebles, R.
- Subjects
- *
THERAPEUTIC use of cytokines , *CELLULAR immunity , *RESPIRATORY syncytial virus , *MICE - Abstract
Abstract: The role of IL-13 in respiratory syncytial virus (RSV) immunopathogenesis is incompletely described. To assess the effect of IL-13 on primary RSV infection, transgenic mice which either overexpress IL-13 in the lung (IL-13 OE) or non-transgenic littermates (IL-13 NT) were challenged intranasally with RSV. IL-13 OE mice had significantly decreased peak viral titers four days after infection compared to non-transgenic littermates. In addition, IL-13 OE mice had significantly lower RSV-induced weight loss and reduced lung IFN-γ protein expression compared with IL-13 NT mice. In contrast, primary RSV challenge of IL-13 deficient mice resulted in a small, but statistically significant increase in viral titers on day four after infection, no difference in RSV-induced weight loss compared to wild type mice, and augmented IFN-γ production on day 6 after infection. In STAT1-deficient (STAT1 KO) mice, where primary RSV challenge produced high levels of IL-13 production in the lungs, treatment with an IL-13 neutralizing protein resulted in greater peak viral titers both four and six days after RSV and greater RSV-induced weight loss compared to mice treated with a control protein. These results suggest that IL-13 modulates illness from RSV-infection. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
39. Respiratory syncytial virus and other pneumoviruses: a review of the international symposium—RSV 2003
- Author
-
Schmidt, Alexander C., Johnson, Teresa R., Openshaw, Peter J.M., Braciale, Thomas J., Falsey, Ann R., Anderson, Lawrence J., Wertz, Gail W., Groothuis, Jessie R., Prince, Gregory A., Melero, Jose A., and Graham, Barney S.
- Subjects
- *
RESPIRATORY syncytial virus , *CONFERENCES & conventions , *ANTIVIRAL agents , *VACCINES , *PARAMYXOVIRUSES , *PREVENTIVE medicine - Abstract
The Respiratory Syncytial Virus 2003 symposium took place from 8th–11th November 2003 in Stone Mountain, Georgia, and brought together more than 200 international investigators engaged in RSV research. RSV biology, pathogenesis, and clinical data, as well as RSV vaccines and antivirals, were addressed in the meeting, and this review will aim to briefly summarize and discuss the implications of new findings. The meeting also served as the inauguration of the Robert M. Chanock Award for lifetime achievement in RSV research, an award named in honor of the person who started the field of RSV research by recovering the first human RS virus from infants with severe bronchiolitis in 1956. [Copyright &y& Elsevier]
- Published
- 2004
- Full Text
- View/download PDF
40. The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates.
- Author
-
Respiratory Syncytial Virus Network (ReSViNET) Foundation, Mazur, Natalie I, Bont, Louis J, Melero, José A, McLellan, Jason S, Englund, Janet A, Karron, Ruth A, Simões, Eric AF, Knezevic, Ivana, Piedra, Pedro A, Langedijk, Annefleur C, Walsh, Edward E, Vekemans, Johan, Higgins, Deborah, Powell, Mair, Satav, Ashish, Graham, Barney S, Nunes, Marta C, Chu, Helen Y, and Ramilo, Octavio
- Subjects
- *
RESPIRATORY syncytial virus , *INFANTS , *GLYCOPROTEINS , *MONOCLONAL antibodies , *VACCINES - Abstract
The global burden of disease caused by respiratory syncytial virus (RSV) is increasingly recognised, not only in infants, but also in older adults (aged ≥65 years). Advances in knowledge of the structural biology of the RSV surface fusion glycoprotein have revolutionised RSV vaccine development by providing a new target for preventive interventions. The RSV vaccine landscape has rapidly expanded to include 19 vaccine candidates and monoclonal antibodies (mAbs) in clinical trials, reflecting the urgency of reducing this global health problem and hence the prioritisation of RSV vaccine development. The candidates include mAbs and vaccines using four approaches: (1) particle-based, (2) live-attenuated or chimeric, (3) subunit, (4) vector-based. Late-phase RSV vaccine trial failures highlight gaps in knowledge regarding immunological protection and provide lessons for future development. In this Review, we highlight promising new approaches for RSV vaccine design and provide a comprehensive overview of RSV vaccine candidates and mAbs in clinical development to prevent one of the most common and severe infectious diseases in young children and older adults worldwide. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.